Sight Sciences, Inc.
NASDAQ:SGHTMedical - Devices
+$0.15 today
- Market cap
- $598.59M
- Beta
- 2.40
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$0.69
Volume 0.34M
Average 0.25M
SGHT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Sight Sciences, Inc.NASDAQ: SGHT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $103K fell 30.9% year over year, behind the +3.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at -11.8% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 0.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -30.9% toward the trailing-twelve-month pace of +3.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 487K USD
- Year-over-year change
- -31.6%
- 4-year CAGR
- -6.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 487K | -31.6% |
| FY2024 | 2024-12-31 | 712K | +16.0% |
| FY2023 | 2023-12-31 | 614K | -13.5% |
| FY2022 | 2022-12-31 | 710K | +12.3% |
| FY2021 | 2021-12-31 | 632K | — |
Depreciation & Amortization vs competitors
How SGHT compares with its peers on the latest reported figures
- SGHT's LTM Mar 2026 depreciation & amortization of $690K is the 6th largest of the 7 companies compared; the peer median is $33.4M.
- Its year-over-year change of +3.1% is the 5th highest of 6, against a peer median of +20.2%.
- Depreciation & amortization amounts to 0.9% of revenue for SGHT, versus a peer median of 8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.84B | +41.7% | +5.9% | 16.9% | |
| LTM Jun 2026 | $1.17B | -5.6% | -4.7% | 10.8% | |
| LTM Jun 2026 | $46.44M | +19.7% | +5.6% | 7.6% | |
| LTM Mar 2026 | $20.35M | +25.1% | +75.1% | 7.6% | |
| LTM Mar 2026 | $4.63M | +20.2% | +27.0% | 8.9% | |
| LTM Mar 2026 | $690K | +3.1% | -11.8% | 0.9% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $612K | — | — | — |
| Peer median (excluding SGHT) | $33.4M | +20.2% | +5.9% | 8.9% | |
Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (62.96M) | (86.24M) | (55.55M) | (51.51M) | (38.43M) |
| Depreciation & Amortization | 632K | 710K | 614K | 712K | 487K |
| Deferred Income Tax | 7.76M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.08M | 12.96M | 14.58M | 17.08M | 13.05M |
| Change in Working Capital | (4.33M) | (5.7M) | (9.13M) | 9M | (6.4M) |
| Accounts Receivables | (3.69M) | (6.84M) | 661K | 3.55M | 912K |
| Inventory | (1.31M) | (3.25M) | (2.16M) | 1.63M | (1.44M) |
| Accounts Payables | 1.17M | (694K) | (883K) | 336K | (348K) |
| Other Working Capital | (486K) | 5.09M | (6.76M) | 3.49M | (5.52M) |
| Other Non-Cash Items | 1.27M | 2.3M | 2.3M | 2.37M | 1.59M |
| Operating Cash Flow | (52.54M) | (75.97M) | (47.18M) | (22.35M) | (29.69M) |
| Capital Expenditures | (813K) | (970K) | (791K) | (385K) | (224K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (813K) | (970K) | (791K) | (385K) | (224K) |
| Debt Repayment | 0 | 0 | 0 | 4.15M | 0 |
| Common Stock Issued | 256.68M | 1.25M | 1.33M | 1.07M | 1.85M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.15M) | 1.25M | (224K) | (261K) | (58K) |
| Financing Cash Flow | 252.53M | 1.25M | 1.1M | 4.96M | 1.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 199.18M | (75.69M) | (46.87M) | (17.77M) | (28.13M) |
| Free Cash Flow | (53.35M) | (76.94M) | (47.98M) | (22.74M) | (29.92M) |
Sight Sciences, Inc.
NASDAQ:SGHT
Intrinsic Alpha fair value
Locked
Current Price
$10.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.